News
Immodulon announces allowability of claims for key European patent application related to lead drug candidate, IMM-101, in combination with immune checkpoint inhibitors
Immodulon announces allowability of claims for key European patent application related to lead drug candidate, IMM-101, in combination with immune checkpoint inhibitors Claims cover IMM-101 in combination with any anti-PD-L1, anti-PD1 or anti-CLTA-4 monoclonal...
First patient enrolled in a phase I/II study for IMM-101 in limited metastatic pancreatic cancer patients at Erasmus University Medical Center
First patient enrolled in a phase I/II study for IMM-101 in limited metastatic pancreatic cancer patients at Erasmus University Medical Center Erasmus MC initiates recruitment for new investigator-sponsored phase I/II study to investigate the safety and efficacy of...
Immodulon to present at the 11th World Clinical Biomarkers & Companion Diagnostic Europe Event on clinical biomarkerstrategies with complex immunomodulators
Presentation on circulatory immunological biomarkers in cancer patients and novel technologies during clinical trials Uxbridge, UK – 15 March 2021 – Immodulon, the immuno-oncology company, announces that its Chief Scientific Officer, Dr. Thomas Kleen, will present at...
Immodulon announces Notices of Allowance and Intention to Grant for four patent applications related to IMM-101 in combination with immune checkpoint inhibitors in US, Japan and Europe
Claims cover methods of treating cancer with IMM-101 in combination with anti-PD-L1, anti-PD1 or anti-CLTA4 antibodies Uxbridge, UK, 8 March 2021 – Immodulon, the immuno-oncology company, today announced that it has received Notices of Allowance from the U.S. Patent...